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ABSTRACT:  
Background: Data on whether T-cell dose of allogeneic peripheral blood stem cell (PBSC) 
product influences transplant outcome are conflicting.    
Methods: Using CIBMTR database, we identified 2,736 adult patients who underwent first 
allogeneic peripheral blood stem cell (PBSC) transplant for acute leukemia (AML, ALL) or 
myelodysplastic syndrome (MDS) between 2008-2014 using an HLA-matched sibling donor 
(MSD) or 8/8-matched unrelated donor (MUD). We excluded ex-vivo and in-vivo T-cell depleted 
transplants. Correlative analysis was performed between CD3+ T-cell dose and risk of graft-
versus-host-disease (GVHD), relapse, non-relapse mortality (NRM), disease free survival (DFS) 
and overall survival (OS).  
Results: Using maximum likelihood estimation method, we identified CD3+ T-cell cell dose 
cutoff that separated risk of acute GVHD (aGVHD) grade II-IV in both MSD and MUD groups. 
A CD3+ T-cell dose cutoff of 14 x10
7
 cells/kg identified MSD/low CD3+ (n=223) and 
MSD/high CD3+ (n=1214), and a dose of 15 x10
7
 cells/kg identified MUD/low CD3+ (n=197) 
and MUD/high CD3+ (n=1102). With univariate analysis, MSD/high CD3+ group had higher 
cumulative incidence of day 100 aGVHD grade II-IV of 33% vs 25% when compared to 
MSD/low CD3+ group (P value =0.009). There was no other difference between both groups in 
engraftment rate, risk of aGVHD grade III-IV or chronic GVHD (cGVHD), NRM, relapse, DFS, 
or OS. MUD/high CD3+ group had higher cumulative incidence of day 100 aGVHD grade II-IV 
of 49% vs 41% when compared to MUD/low CD3+ group (P value =0.04). There was no other 
difference between both groups in engraftment rate, risk of severe aGVHD or cGVHD, NRM, 
relapse, DFS, or OS. Multivariate analysis of MSD and MUD groups failed to show an 
association between CD3+ T-cell dose and risk of either aGVHD grade II-IV (p value =0.1 and 
0.07 respectively) or cGVHD (p value=0.8 and 0.3 respectively). Sub-analysis of CD4, CD8 and 
CD4/CD8 ratio failed to identify cutoff values predictive of transplant outcome. Using log-rank 
test, the sample size was, however, suboptimal to identify difference at these cutoff cell dose.  
Conclusion: In this registry study, CD3+ T-cell dose of PBSCT product did not influence risk of 
aGVHD or cGVHD or other transplant outcomes when using HLA-matched sibling or 8/8 
unrelated donors. Subset analysis of CD4+ and CD8+ T-cell dose was not possible for small 
sample size.    
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INTRODUCTION 
Allogeneic hematopoietic cell transplant (HCT) when performed for hematologic malignancies, 
relies on both conditioning regimen as well as the immunotherapy exploiting the graft versus 
tumor (GVT) effect, which is primarily derived from donor immune effector cells.
1, 2
 A complex 
interplay between the immune effector cells including antigen presenting cells, CD3 + cells 
(CD4+ T cells, CD8+ T cells, regulatory T cells (T regs)), and natural killer (NK) cells is 
responsible for both the GVT and the graft-versus-host-disease (GVHD)
3
, among which the most 
well-studied cells are the CD3+ T-cells.  
Though the CD3+ T-cells can exert a strong GVT
4
, the risk of aGVHD also rises with a higher 
dose as demonstrated by both observational and prospective studies.
5, 6
 T-cell depleted (TCD) 
allogeneic HCT have led to a decreased risk of GVHD but at an expense of increasing the risk of 
relapse, as demonstrated by some trials in both ex-vivo
7
 and in-vivo depletion
8
.  The higher risk 
of GVHD in peripheral blood stem cell (PBSC) graft compared to the bone marrow (BM) source 
is apparent from both observational studies
9
 and clinical trials
10
 as the PBSCs are known to carry 
10-15 times the quantity of CD3+ T-cells comparatively.
11
 Thus many attempts have been made 
to separate out the GVT from GVHD which include utilizing CD34+ selection
12
, naïve T-cell 
depletion
13
, post-transplant cyclophosphamide
14
, microtransplantation
15
 and NK-cell graft 
engineering. Few single center studies have evaluated the role of CD3+ T-cell dose with respect 
to both relapse and GVHD outcomes post-HCT, however, these studies varied significantly in 
the selection criteria with no consensus on an optimal CD3+ T-cell dose cutoff value.
16-19
 A 
recent large registry study indicated that in HCTs utilizing unrelated donors, the CD3+ and 
CD34+ doses were significantly associated with an increased risk for grade III-IV  aGVHD 
(hazard ratio [HR] = 3.6; 95% CI: 1.45-9.96, P = .006 and 2.65 (95% CI: 1.07-6.57), P = .04, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
5 
 
respectively).
20
 Since the studies mentioned above have used different types of donors, different 
diseases, and different conditioning regimens, optimum cut-offs for the CD3+ T-cell dose which 
can potentially avoid GVHD while still promote GVT, are unknown.  
We hypothesized that there exists a  T-cell dose range that promotes GVT while levels above this 
range result in higher risk of both severe acute and chronic GVHD with subsequent increased 
non-relaspe mortality (NRM).  
 
MATERIALS and METHODS 
Data sources 
The Center for International Blood and Marrow Transplant Research (CIBMTR) is a working 
group of more than 420 transplantation centers worldwide that contribute detailed data on HCT 
to a statistical center at the Medical College of Wisconsin. Participating centers are required to 
report all transplantations consecutively; patients are followed longitudinally and compliance is 
monitored by on-site audits. Computerized checks for discrepancies, physicians' review of 
submitted data, and on-site audits of participating centers ensure data quality. Observational 
studies conducted by the CIBMTR are performed in compliance with all applicable federal 
regulations pertaining to the protection of human research participants. Protected Health 
Information used in the performance of such research is collected and maintained in CIBMTR’s 
capacity as a Public Health Authority under the HIPAA Privacy Rule. The Institutional Review 
Boards of the Medical College of Wisconsin and the National Marrow Donor Program approved 
this study. The CIBMTR collects data at two levels: Transplant Essential Data (TED) and 
Comprehensive Report Form (CRF) data. TED level data include disease type, age, gender, pre-
HCT disease stage and chemotherapy-responsiveness, date of diagnosis, graft type (bone 
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marrow- and/or blood-derived stem cells), conditioning regimen, post-transplant disease 
progression and survival, development of a new malignancy, and cause of death. All CIBMTR 
centers contribute TED data. More detailed disease and pre- and post-transplant clinical 
information are collected on a subset of registered patients selected for CRF data by a weighted 
randomization scheme. TED and CRF level data are collected pre-transplant, 100 days, and six 
months post-HCT and annually thereafter or until death. Data for the current analysis were 
retrieved from CIBMTR (TED and CRF) report forms. 
Patients 
We analyzed data of adult (≥18 years) patients who underwent first allogeneic HCT for acute 
myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome 
(MDS) between 2008 and 2014 with PBSC using HLA-identical sibling donor (MSD) or 8/8-
matched unrelated donor (MUD) matched at the allele-level at HLA-A, -B, -C and -DRB1. We 
limited the disease types to AML, ALL, and MDS hypothesizing that these patients have 
comparable risk of relapse and susceptibility to GVT effect. We excluded ex-vivo (TCD and 
CD34 selected grafts) and in-vivo TC  (antithymoglobulin or alemtuzumab) HCT. All patients 
had available CD3+ T-cell dose, however, some patients were missing CD4+ T-cell and/or 
CD8+ T cell dose.    
Definitions of endpoints 
For overall survival (OS), death from any cause was considered an event and surviving patients 
were censored at last contact. For disease-free survival (DFS), either progression/relapse or death 
from any cause was considered an event while patients alive without evidence of disease 
relapse/progression were censored at last follow-up. Non-relapse mortality (NRM) was defined 
as death without evidence of primary disease progression/relapse with the latter event considered 
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a competing risk. AGVHD and cGVHD were graded using standard criteria
21, 22
 Neutrophil 
recovery was defined as the first of 3 successive days with absolute neutrophil count (ANC) 
≥500/µL after post-transplantation nadir. Platelet recovery was defined as the first of 3 
successive days with platelet counts ≥20,000/μL without transfusion support for at least 7 days. 
Data are censored for mortality events before neutrophil recovery.  
Statistical analysis 
The primary objective of the study was to correlate the graft T-cell dose with the incidence and 
grade of aGVHD and cGVHD, OS, DFS, relapse and NRM following PBSC HCT in matched 
sibling and 8/8 matched URD HCT. In a subset analysis for subjects with available CD4+, CD8+ 
T-cell doses, we also tested for association of the graft T-cell subset dose and the ratio of 
CD4+/CD8+ T-cell and these transplant outcomes in univariate analysis only due to smaller 
sample size. T-cell dose cutoff values were determined using maximum likelihood method based 
on Cox proportional hazards model for aGVHD grade II-IV endpoint. 
Categorical data were summarized using frequencies while continuous data were summarized 
using medians and ranges. Probabilities of DFS and OS were calculated as described 
previously.
23
 Cumulative incidence of aGVHD grade II-IV, aGVHD grade III-IV, cGVHD, 
NRM, relapse/progression, platelet recovery and hematopoietic recovery were calculated to 
accommodate for competing risks.
24
 Associations among patient-, disease-, and transplantation-
related variables and outcomes of interest were evaluated using Cox proportional hazards 
regression. All the clinical variables were tested for the affirmation of the proportional hazards 
assumption. Factors violating the proportional hazards assumption were adjusted through 
stratification. Then a stepwise forward model selection procedure was used to select adjusted 
clinical variables for each outcome with a threshold of 0.05 for both entry and stay in the model. 
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Interactions between T-cell dose and the adjusted  clinical variables were examined and no 
significant interactions were detected. Center effect was adjusted as a random factor for all 
outcomes.
25
 The significance level of 0.01 was used for the overall effects of factors followed by 
Bonferroni adjustment for pairwise comparisons to account for multiple testing. All statistical 
analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) 
RESULTS:  
Baseline Characteristics 
We identified 2,736 adult patients who met the selection criteria described above. Regimen 
intensity as myeloablative (MAC), reduced intensity (RIC), or non-myeloablative (NMA)was 
defined as previously described.
26
 Based on Cox proportional hazards model, we detertmined the 
cutoff value for CD3+ T-cell dose and separated each group (MSD and MUD) into low and high 
risk of grade II-IV aGVHD. These were 14 x10
7
 cells/kg and 15 x10
7
 cells/kg for MSD and 
MUD groups respectively. Then, patients were divided into 4 groups based on the donor type 
(MSD or MUD) and T-cell dose cutoff values. The 4 groups were MSD/low CD3+ (n= 223), 
MSD/high CD3+ (n= 1214), MUD/low CD3+ (n= 197), MUD/high CD3+ (n= 1102). Median 
CD3+ T-cell dose were 11 and 29 (x 10
7
) in the MSD/Low and MSD/High groups, respectively, 
and 10 and 28 (x10
7
) in the MUD/Low and MUD/High groups respectively. MSD and MUD 
groups were analyzed separately. The baseline patient-, disease- and transplantation-related 
characteristics are shown in Tables 1 and 2.  
Matched sibling donor (MSD) groups   
Univariate analysis showed cumulative incidence of aGVHD grade II-IV at day +100 of 25% 
(95% CI [confidence interval]: 19-31) and 33% (95% CI: 30-36) in MSD/low CD3+ and 
MSD/high CD3+ respectively (p = 0.009). However, there was no difference in the risk of 
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aGVHD grade III-IV (p= 0.4). Likewise, risk of cGVHD at 2 years, NRM, relapse, DFS, and OS 
were not shown to be statistically different. There was also no difference in the day 100 
engraftment rate between both groups.   
In multivariate analysis, CD3+ T-cell dose did not influence aGVHD (II-IV, and III-IV) (Table 
3), cGVHD, relapse, NRM, DFS, or OS (Supplemental Table 1). However, aGVHD grade II-IV 
risk was higher with any gender mismatch (p = 0.02 and 0.009 for female-male and male-female, 
respectively). Risk of severe  aGVHD grade III-IV was worse among patients with lower 
Karnofsky Performance Status (KPS) (<90) relative to KPS 90-100 (p = 0.005). Risk of cGVHD 
was worse in patients older than 29 years old (overall p = 0.006), with female donors (p = 
<0.002), and in transplant done before 2011 (p = 0.01). DFS was worse among older patients 
(≥60 years old) (p = 0.01), high/very high Disease Risk Index (DRI) (p <0.0001), and lower KPS 
(p = <0.0001)]. OS was worse among high/very high DRI (p = 0.0001), lower KPS (p = 
<0.0001), and HCT-CI >3 (p = 0.003). Non-relapse mortality was worse among MDS (p = 
0.002), lower KPS (p = 0.007), and HCT-CI >3 (p = 0.0006). Relapse risk was worse among 
patients with advanced disease prior to transplant (p = 0.0007), and lower KPS (p = 0.002).   
Subset analysis of CD4, CD8 and CD4/CD8 ratio was available only in limited number of 
patients. No significant association of these variables were detected for aGVHD, cGVHD, NRM, 
relapse, DFS, or OS. Likewise, CD34+ cell dose was also not significantly associated with any 
of the transplant outcomes.   
Matched unrelated donor (MUD) groups   
Univariate analysis showed cumulative incidence of aGVHD grade II-IV at day +100 of 41% 
(95% CI: 35-48) and 49% (95% CI: 46-52) in MUD/low CD3+ and MUD/high CD3+ 
respectively (p = 0.04). However, there was no difference in the risk of aGVHD grade III-IV (p= 
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0.9). Likewise, risk of cGVHD at 2 years, NRM, relapse, DFS, and OS were not statistically 
different. There was also no difference in the day 100 engraftment rate between both groups.   
In multivariate analysis, CD3+ T-cell dose did not influence risk of aGVHD (II-IV, and III-IV) 
(Table 4), cGVHD, relapse, NRM, DFS, or OS (Supplemental Table 2). However, aGVHD 
grade II-IV risk was higher among patients who received myeloablative regimens (P = 0.02). 
Risk of severe aGVHD grade III-IV was worse among underweight patients (p = 0.01), and with 
older donors (>32 years old) (p = 0.01). Risk of cGVHD was less in patients with ALL (p = 
0.003), and in transplant done after 2010 (p = 0.0003). DFS was worse with older donors (>50 
years old) (p = 0.0001), and high/very high DRI (p < 0.0003). OS  had a worse outcome among 
older patients (≥50 years old) (p = 0.008), older donor (≥50 years old) (p = 0.0001), high/very 
high DRI (p = 0.0005), and lower KPS (p = <0.009). Non-relapse mortality was worse with older 
donor (>50 years old) (p = 0.0006). Relapse risk was worse among patients with high/very high 
DRI (p = 0.0002).  Subset analysis of CD4, CD8 and CD4/CD8 ratio was available only in 
limited number of patients. No significant association of these variables were detected for 
aGVHD, cGVHD, NRM, relapse, DFS, or OS. Likewise, CD34+ cell dose was also not 
significantly associated with any of the transplant outcomes.     
DISCUSSION 
This study demonstrated no association of the CD3+ T-cell dose of PBSC graft and risk of acute 
or chronic GVHD, nor did it influence the risk of relapse in the cohort. Nonetheless, the 
subgroup analyses project certain associations worth exploring further prospectively. Although 
the univariate analysis showed a correlation between the CD3+ T-cell dose and the risk of 
aGVHD in both the MSD and the MUD groups, the multivariable analysis failed to prove such 
an association. It is possible that the subgroups selected for multivariate analysis were not large 
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enough to power a detection in difference in the binary outcome (presence or absence of grade 
II-IV aGVHD) thus leading to the possibility of type II error. It is also possible that the variables 
chosen in the univariate analysis did not include some potential risk factors of aGVHD (e.g. 
inadequate information on CD4+, CD8+, CD56+ cells, and dendritic cells in the PBSC graft). 
The only group with increased risk of aGVHD grade II-IV (on multivariate analysis) was 
patients who underwent MUD HCT using MAC regimens. This is consistent with the previous 
CIBMTR study that showed that among MUD HCT, RIC regimens were associated with 
decreased risk of aGVHD.
27
   
Our data contrasts with the European Society of Blood and Marrow Transplant (EBMT) study of 
MUD HCT that showed that CD3+ T-cell dose >35 × 10
7
/kg to be associated with higher risk of 
aGVHD.
20
 This discrepancy may be attributed to difference in median CD3+ T-cell doses in 
PBSC grafts in both studies, and the statistical methodology used for categorization of the 
primary outcome variable (CD3+ T-cell dose was categorized by interquartile range in the 
EBMT study, whereas in the current study we used a cutoff values of CD3 T-cell dose based on 
the differential risk of aGVHD grade II-IV). Moreover, EBMT study included TCD allogeneic 
HCT, whereas the current study excluded it. Additionally, some of the conditioning regimens 
used in the EBMT study were not evaluated in the current study. It is worthy noting that the 
BMT CTN0201 trial has also failed to show an association of the T-cell dose of the PBSC graft 
with survival or GVHD in patients with AML or MDS.
28
 A single institurion study using bone 
marrow (rather than PBSC) graft has demonstrated a paradoxical increase of risk of cGVHD 
with lower CD3+ T-cell dose in a subset of patients who received myeloablative  
busulfan/cyclophosphamide regimen (p=0.006).
29
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Due to the limited sample size of our cohort, further analysis was not possible in order to detect 
outcome differences based on T cell phenotypic subsets; CD4+, CD8+, or their ratio. However, 
transplant outcome may depend on functional T cell subsets; naïve T cells, effector T cells, 
and/or central memory T cells. In particular, depletion of naïve T cells (either CD4+ or CD8+) 
was associated with less risk of cGVHD and more likelihood of steroid-responsive aGVHD in 
small phase II study.
13
 Treg (regulatory T cells: CD4+/CD25+/FOXP3+) another small subset of 
CD4 has been shown to ameleriorate cGVHD.
30
 Unbalanced recovery of Treg and effector T cells 
after transplant has been also correlated with risk of cGVHD.
31
  
Though, a PBSC graft includes a co-infusion of both CD34+ and CD3+ T-cells in HCTs, the 
dose of CD3+ is not evaluated routinely in most transplant centers since it continues to be 
controversial. Farhan et al. retrospectively evaluated the CD3+ T-cell dose in both MUD and 
MSD HCTs, and found no significant correlation with aGVHD, however, they observed that the 
OS was significantly affected by a higher dose of CD3+ (mean dose 12 x 10^7/kg) in their 
cohort.
32
  This CD3+ T-cell dose differs from the dose in our cohort and the EBMT cohort, thus 
perhaps contributing to different outcome.   
Although, our analysis did not show an impact of CD34+ cell dose on transplant outcome, it is 
worth noting that most of patients in our cohorts (more than 50%) received CD34+ cell dose of 
4-8 x10*6 cells/kg and minority (5-10%) received a dose <2 x10*6 cells/kg (tables 1 and 2). In 
our opinion, this precludes an accurate conclusion on the impact of CD34+ cell dose on 
transplant outcome. Prior studies have evaluated this question with favorable outcome with 
higher CD34+ cell dose
33-35
 albeit observing higher risk of cGVHD with CD34+ cell dose >8 
x10*6 cells/kg,
35, 36
 or >10 x10*6 cells/kg.
37
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Donor age group was found to be a risk factor for the development of severe aGVHD and for a 
worse DFS (donor age > 50 years) in MUD HCT. The effect of donor age on the clinical 
outcomes is similar to another study,
16
 where there was a correlation of donor’s age and the 
CD8+ content of the PBSC graft. Given the limited availability of CD8+ dose in the PBSC grafts 
in our cohorts, we could not assess this association with age. This study was congruent with 
other large studies for results pertaining to well known risk factors for GVHD, e.g. older 
recipient age
38
, and a lower KPS
39
. Expectedly, a higher DRI predicted greater risk of relapse in 
both MUD and MSD groups.
40
  
Strength of our study lies in a large sample size in both the MUD and MSD groups, which 
allowed us to categorize the entire cohort into 4 groups based on the donor and the CD3+ T-cell 
dose in the PBSC graft. Another strength of the study was the availability of comprehensive data 
on both the transplant (including both MAC and RIC/NMA regimens) and disease associated 
risk factors (in the 3 disease types selected for the study), and a long median follow-up of 4 years 
(49 months for MSD, 47 months for MUD).  
To our knowledge, this is the largest study addressing the question of impact of T-cell content of 
PBSC grafts on transplant outcomes. In this registry study, the CD3+ T-cell dose in the PBSCT 
product did not influence the risk of aGVHD or cGVHD or other transplant outcomes when 
using HLA- matched sibling or 8/8 unrelated donors. Prospective studies are needed to determine 
whether T-cell subsets; CD4+, CD8+, Treg, or naïve T-cell content of the allografts have 
meaningful influence on transplant outcome. Results of the ongoing phase II clinical trial using 
standardized CD3+ T cell dose with HLA-matched related PBSC transplant is awaited 
(NCT00959140). Additionally, in the current era of post-transplant cyclophosphamide (PTCy) 
for prevention of GVHD, it may be imperative to assess the impact of these T-cell subsets in 
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haploidentical and HLA-matched HCT. Interestingly, a multicenter study has indeed indicated an 
increased risk of all grade cGVHD with an elevated CD3+ T-cell dose with haploidentical PBSC 
HCT using post-transplant cyclophosphamide.
41
 CD3 T-cell dose has also been shown to be 
predictive of graft failure with TCD allogeneic HCT.
42
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Table 1. Characteristics of adult patients undergoing first allogeneic HCT for AML, ALL, and 
MDS between 2008-2014 with PBSC from an HLA-identical sibling donor with valid CD3+ cell 
dose data, as reported to the CIBMTR. 
 
CD3+ T-cell dose < 14 x10
7
 > 14 x10
7
 
Number of patients 223 1214 
Number of centers 58 95 
Recipient Age   
 Median (range) 51 (18-71) 54 (18-78) 
 18-29 20 (9) 110 (9) 
 30-39 28 (13) 130 (11) 
 40-49 55 (25) 232 (19) 
 50-59 74 (33) 419 (35) 
 60+ 46 (21) 323 (27) 
Recipient gender   
 Male 123 (55) 694 (57) 
 Female 100 (45) 520 (43) 
Recipient race   
 Caucasian 176 (79) 1057 (87) 
 Non-Caucasian 37 (17) 117 (10) 
 Missing 10 (4) 40 (3) 
Body mass index   
 Median (range) 29 (18-62) 27 (15-56) 
 Underweight (<18.5) 2 (<1) 25 (2) 
 Normal (18.5-<25) 52 (23) 366 (30) 
 Overweight (25-<30) 67 (30) 433 (36) 
 Obese (>30) 101 (45) 390 (32) 
 Missing 1 (<1) 0 
Karnofsky performance status   
 < 90 92 (41) 478 (39) 
 90-100 125 (56) 718 (59) 
 Missing 6 (3) 18 (1) 
Sorror co-morbidity index   
 0-1 101 (45) 560 (46) 
 2-3 68 (30) 382 (31) 
 4+ 51 (23) 261 (21) 
 Missing 3 (1) 11 (<1) 
Disease   
 AML 137 (61) 640 (53) 
 ALL 33 (15) 224 (18) 
 MDS 53 (24) 350 (29) 
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CD3+ T-cell dose < 14 x10
7
 > 14 x10
7
 
Disease status   
 AML 137 640 
  Early 87 (64) 386 (60) 
  Intermediate 21 (15) 107 (17) 
  Advanced 29 (21) 147 (23) 
 ALL 33 224 
  Early 17 (52) 167 (75) 
  Intermediate 7 (21) 37 (17) 
  Advanced 9 (27) 20 (9) 
 MDS 53 350 
  Early 35 (66) 228 (65) 
  Intermediate 17 (32) 104 (30) 
  Advanced 1 (2) 18 (5) 
Revised Disease Risk Index (DRI)   
 AML 137 640 
  Low 8 (6) 41 (6) 
  Intermediate 90 (66) 355 (55) 
  High/Very high 25 (18) 135 (21) 
  Missing 14 (10) 109 (17) 
 ALL 33 224 
  Intermediate 17 (52) 167 (75) 
  High/Very high 16 (48) 57 (25) 
 MDS 53 350 
  Intermediate 29 (55) 194 (55) 
  High/Very high 12 (23) 81 (23) 
  Missing 12 (23) 75 (21) 
Time from diagnosis to transplant, months   
 Median (range) 6 (1-156) 5 (<1-279) 
 < 6 121 (54) 695 (57) 
 6 - < 12 52 (23) 257 (21) 
 > 12 50 (22) 262 (22) 
CD3+ cell dose, x 10
7
/kg, median (range) 11 (3-14) 29 (14-113) 
CD4+ cell dose, x 10
7
/kg, quartiles   
 Median (range) 8 (3-169) 19 (<1-180) 
 < 10.6 73 (33) 30 (2) 
 10.6 - 16.79 4 (2) 99 (8) 
 16.8 - 28.79 0 103 (8) 
 > 28.8 12 (5) 90 (7) 
 Missing 134 (60) 892 (73) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
22 
 
CD3+ T-cell dose < 14 x10
7
 > 14 x10
7
 
CD8+ cell dose, x 10
7
/kg, quartiles   
 Median (range) 4 (<1-59) 8 (<1-253) 
 < 4.52 61 (27) 43 (4) 
 4.52 - 7.179 16 (7) 87 (7) 
 7.18 - 12.769 2 (<1) 102 (8) 
 > 12.77 11 (5) 92 (8) 
 Missing 133 (60) 890 (73) 
CD34+ cell dose, x 10
6
/kg   
 Median (range) 5 (<1-22) 6 (<1-28) 
 < 2 36 (16) 53 (4) 
 2-<4 54 (24) 211 (17) 
 4-<8 101 (45) 624 (51) 
 > 8 26 (12) 314 (26) 
 Missing 6 (3) 12 (<1) 
CD4+/CD8+ cell dose ratio, quartiles   
 Median (range) 2 (<1-9) 2 (<1-13) 
 < 1.53 26 (12) 78 (6) 
 1.53 - 2.189 20 (9) 82 (7) 
 2.19 - 3.149 23 (10) 79 (7) 
 > 3.15 19 (9) 84 (7) 
 Missing 135 (61) 891 (73) 
D/R gender match   
 F/F 48 (22) 255 (21) 
 F/M 55 (25) 312 (26) 
 M/F 52 (23) 265 (22) 
 M/M 68 (30) 382 (31) 
D/R CMV status match   
 -/- 56 (25) 276 (23) 
 -/+ 52 (23) 304 (25) 
 +/- 26 (12) 141 (12) 
 +/+ 84 (38) 477 (39) 
 Missing 5 (2) 16 (1) 
D/R ABO match   
 Matched 105 (47) 565 (47) 
 Minor mismatch 26 (12) 136 (11) 
 Major mismatch 22 (10) 149 (12) 
 Bidirectional mismatch 7 (3) 36 (3) 
 Missing 63 (28) 328 (27) 
Conditioning regimen intensity   
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CD3+ T-cell dose < 14 x10
7
 > 14 x10
7
 
 MA 167 (75) 840 (69) 
 RIC/NMA 56 (25) 374 (31) 
Conditioning regimen, MA   
 BU+CY+others 52 (31) 242 (29) 
 TBI+CY 48 (29) 275 (33) 
 BU+FLU 40 (24) 206 (25) 
 TBI+ETOP 10 (6) 71 (8) 
 Others  17 (10) 46 (5) 
Conditioning regimen, RIC/NMA   
 BU+FLU 20 (36) 156 (42) 
 FLU+MEL 23 (41) 104 (28) 
 TBI+FLU 2 (4) 64 (17) 
 FLU+others 10 (18) 41 (11) 
 Others 1 (2) 9 (2) 
TBI used in conditioning regimen   
 Yes 81 (36) 461 (38) 
 No 142 (64) 753 (62) 
GVHD prophylaxis   
 CsA + MTX + others 9 (4) 123 (10) 
 Tac + MTX + others 161 (72) 716 (59) 
 CsA + MMF + others 13 (6) 92 (8) 
 Tac + MMF + others 18 (8) 145 (12) 
 Others 22 (10) 138 (11) 
Year of transplant   
 2008-2010 110 (49) 555 (46) 
 2011-2014 113 (51) 659 (54) 
Follow-up of survivors, months, median (range) 47 (3-101) 49 (3-107) 
Abbreviations: HCT, hematopoietic cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic 
leukemia; MDS, myelodysplastic syndrome; PBSC, peripheral blood stem cells; HLA, human leukocyte antigen; 
CIBMTR, Center for Blood and Marrow Transplant Research; D, donor; R, recipient; F, female; M, male; CMV, 
cytomegalovirus, MA, myeloablative; RIC/NMA, reduced intensity conditioning/non-myeloablative, BU, busulfan; 
CY, cyclophosphamide; TBI, total body irradiation; FLU, fludarabine; ETOP, etoposide; GVHD, graft-versus-host 
disease; CsA, cyclosphamide; MTX, methotrexate; MMF, mycophenolate mofetil; Tac, tacrolimus. 
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Table 2: Characteristics of adult patients undergoing first allogeneic HCT for AML, ALL, and 
MDS between 2008-2014 with PBSC from an 8/8-matched unrelated donor with valid CD3+ cell 
dose data, as reported to the CIBMTR. 
 
Variable < 15 x10
7
 > 15 x10
7
 
Number of patients 197 1102 
Number of centers 55 80 
Age   
 Median (range) 55 (19-76) 56 (18-78) 
 18-29 18 (9) 111 (10) 
 30-39 25 (13) 120 (11) 
 40-49 32 (16) 182 (17) 
 50-59 61 (31) 264 (24) 
 60+ 61 (31) 425 (39) 
Recipient gender   
 Male 123 (62) 629 (57) 
 Female 74 (38) 473 (43) 
Recipient race   
 Caucasian 190 (96) 1022 (93) 
 Non-Caucasian 7 (4) 61 (6) 
 Missing 0 19 (2) 
Body mass index, median (range)   
Body mass index   
 Median (range) 29 (19-52) 28 (8-62) 
 Underweight (<18.5) 0 21 (2) 
 Normal (18.5-<25) 45 (23) 309 (28) 
 Overweight (25-<30) 68 (35) 418 (38) 
 Obese (>30) 84 (43) 354 (32) 
Karnofsky performance status   
 < 90 81 (41) 428 (39) 
 90-100 113 (57) 662 (60) 
 Missing 3 (2) 12 (1) 
Sorror co-morbidity index   
 0-1 64 (32) 473 (43) 
 2-3 61 (31) 357 (32) 
 4+ 70 (36) 264 (24) 
 Missing 2 (1) 8 (<1) 
Disease   
 AML 116 (59) 619 (56) 
 ALL 22 (11) 142 (13) 
 MDS 59 (30) 341 (31) 
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Variable < 15 x10
7
 > 15 x10
7
 
Disease status   
 AML 116 619 
  Early 70 (60) 351 (57) 
  Intermediate 20 (17) 124 (20) 
  Advanced 26 (22) 141 (23) 
  Missing 0 3 (<1) 
 ALL 22 142 
  Early 12 (55) 91 (64) 
  Intermediate 5 (23) 31 (22) 
  Advanced 5 (23) 20 (14) 
 MDS 59 341 
  Early 41 (69) 233 (68) 
  Advanced 16 (27) 92 (27) 
  Missing 2 (3) 16 (5) 
Revised Disease Risk Index (DRI)   
 AML 116 619 
  Low 9 (8) 39 (6) 
  Intermediate 64 (55) 352 (57) 
  High/Very high 26 (22) 129 (21) 
  Missing 17 (15) 99 (16) 
 ALL 22 142 
  Intermediate 12 (55) 91 (64) 
  High/Very high 10 (45) 51 (36) 
 MDS 59 341 
  Intermediate 33 (56) 210 (62) 
  High/Very high 11 (19) 73 (21) 
  Missing 15 (25) 58 (17) 
Time from diagnosis to transplant, months   
 Median (range) 6 (2-156) 6 (<1-297) 
 < 6 94 (48) 505 (46) 
 6 - < 12 55 (28) 292 (26) 
 > 12 47 (24) 305 (28) 
 Missing 1 (<1) 0 
CD3+ cell dose, x 10
7
/kg, median (range) 10 (3-14) 28 (14-113) 
CD4+ cell dose, x 10
7
/kg, quartiles   
 Median (range) 6 (2-57) 18 (<1-190) 
 < 9.6 63 (32) 20 (2) 
 9.6 - 14.89 3 (2) 80 (7) 
 14.9 - 23.39 0 81 (7) 
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Variable < 15 x10
7
 > 15 x10
7
 
 > 23.4 6 (3) 77 (7) 
 Missing 125 (63) 844 (77) 
CD8+ cell dose, x 10
7
/kg   
 Median (range) 4 (<1-30) 10 (<1-145) 
 < 5.19 58 (29) 24 (2) 
 5.19 - 8.519 8 (4) 76 (7) 
 8.52 - 14.439 1 (<1) 81 (7) 
 > 14.44 5 (3) 78 (7) 
 Missing 125 (63) 843 (76) 
CD34+ cell dose, x 10
6
/kg   
 Median (range) 5 (<1-24) 7 (1-30) 
 < 2 10 (5) 11 (<1) 
 2-<4 40 (20) 98 (9) 
 4-<8 117 (59) 511 (46) 
 > 8 27 (14) 455 (41) 
 Missing 3 (2) 27 (2) 
CD4+/CD8+ cell dose ratio   
 Median (range) 2 (<1-6) 2 (<1-19) 
 < 1.31 19 (10) 62 (6) 
 1.31 - 1.649 14 (7) 68 (6) 
 1.65 - 2.259 19 (10) 65 (6) 
 > 2.26 20 (10) 62 (6) 
 Missing 125 (63) 845 (77) 
Unrelated donor age, years   
 Median (range) 30 (18-60) 28 (18-61) 
 18-32 116 (59) 692 (63) 
 33-49 59 (30) 296 (27) 
 50+ 14 (7) 63 (6) 
 Missing 8 (4) 51 (5) 
D/R gender match   
 F/F 15 (8) 163 (15) 
 F/M 19 (10) 174 (16) 
 M/F 59 (30) 310 (28) 
 M/M 104 (53) 455 (41) 
D/R CMV status match   
 -/- 65 (33) 300 (27) 
 -/+ 71 (36) 409 (37) 
 +/- 15 (8) 116 (11) 
 +/+ 42 (21) 265 (24) 
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Variable < 15 x10
7
 > 15 x10
7
 
 Missing 4 (2) 12 (1) 
D/R ABO match   
 Matched 60 (30) 397 (36) 
 Minor mismatch 42 (21) 216 (20) 
 Major mismatch 34 (17) 168 (15) 
 Bidirectional mismatch 5 (3) 66 (6) 
 Missing 56 (28) 255 (23) 
Conditioning regimen intensity   
 MA 134 (68) 668 (61) 
 RIC/NMA 63 (32) 434 (39) 
Conditioning regimen, MA   
 BU+CY+others 50 (37) 211 (32) 
 TBI+CY 33 (25) 157 (24) 
 BU+FLU 29 (22) 203 (30) 
 TBI+ETOP 6 (4) 29 (4) 
 Others  16 (12) 68 (10) 
Conditioning regimen, RIC/NMA   
 BU+FLU 27 (43) 117 (27) 
 FLU+MEL 20 (32) 145 (33) 
 TBI+FLU 8 (13) 100 (23) 
 FLU+others 6 (10) 43 (10) 
 Others 2 (3) 29 (7) 
TBI used in conditioning regimen   
 Yes 57 (29) 391 (35) 
 No 140 (71) 711 (65) 
GVHD prophylaxis   
 CsA + MTX + others 6 (3) 41 (4) 
 Tac + MTX + others 130 (66) 611 (55) 
 CsA + MMF + others 11 (6) 97 (9) 
 Tac + MMF + others 30 (15) 192 (17) 
 Others 20 (10) 161 (15) 
Year of transplant   
 2008-2010 69 (35) 482 (44) 
 2011-2014 128 (65) 620 (56) 
Follow-up of survivors, months, median (range) 37 (21-96) 48 (3-102) 
Abbreviations: HCT, hematopoietic cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic 
leukemia; MDS, myelodysplastic syndrome; PBSC, peripheral blood stem cells; HLA, human leukocyte antigen; 
CIBMTR, Center for Blood and Marrow Transplant Research; D, donor; R, recipient; F, female; M, male; CMV, 
cytomegalovirus, MA, myeloablative; RIC/NMA, reduced intensity conditioning/non-myeloablative, BU, busulfan; 
CY, cyclophosphamide; TBI, total body irradiation; FLU, fludarabine; ETOP, etoposide; GVHD, graft-versus-host 
disease; CsA, cyclosphamide; MTX, methotrexate; MMF, mycophenolate mofetil; Tac, tacrolimus. 
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Table 3: Multivariate analysis of MSD showing influence of CD3+ T-cell dose.  
 
 aGVHD II-IV 
* 
aGVHD III-
IV* 
cGVHD* Relapse ** NRM DFS OS 
Factor HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
CD3 
cell 
dose, x 
107/kg 
 
              
> 14 1  1  1  1  1  1  1  
< 14 0.79 
(0.60-
1.04) 
0.10 0.78 
(0.51-
1.18) 
0.25 0.97 
(0.79-
1.21) 
0.81 1.02 
(0.81-
1.29) 
0.85 0.97 
(0.70-
1.36) 
0.87 0.99 
(0.82-
1.20) 
0.96 0.94 
(0.77-
1.15) 
0.55 
 Abbreviations: MSD, matched sibling donor; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-
versus-host disease. 
 
 
 
 
Table 4: Multivariate analysis of MUD groups showing influence of CD3+ T-cell dose. 
 
 aGVHD II-IV 
* 
aGVHD III-
IV** 
cGVHD Relapse NRM DFS OS 
Factor HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
HR 
(95% 
CI) 
P 
value 
CD3 
cell 
dose, x 
107/kg 
 
              
> 15 1  1  1  1  1  1  1  
< 15 0.81 
(0.65-
1.02) 
0.07 0.85 
(0.61-
1.19) 
0.34 0.89 
(0.73-
1.10) 
0.29 1.01 
(0.78-
1.29) 
0.96 0.95 
(0.71-
1.27) 
0.73 0.97 
(0.80-
1.18) 
0.77 0.96 
(0.78-
1.17) 
0.66 
Abbreviations: MUD, matched unrelated donor; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-
versus-host disease. 
 
 
